AbbVie reports clinical data showing benefits of endometriosis therapy

AbbVie has announced new clinical data showing the benefits of the oral treatment elagolix for the management of endometriosis with associated pain.

In cooperation with Neurocrine Biosciences, the company has presented detailed results from two replicate phase III extension studies evaluating the long-term efficacy and safety of elagolix, an investigational gonadotropin-releasing hormone antagonist.

Elagolix was shown to have demonstrated a sustained reduction in average monthly menstrual pelvic pain and non-menstrual pelvic pain in women throughout the 12-month treatment period.

Additionally, the safety and tolerability of elagolix was shown to be consistent with the anticipated effects of reduced estradiol levels, with no new safety concerns associated with elagolix use for the 12-month treatment period.

Dr Shao-Lee Lin, vice-president for therapeutic areas and international development at AbbVie, said: "There have been few recent scientific advancements for women suffering from endometriosis and physicians are in need of additional treatment options to help manage this debilitating disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.